For research use only. Not for therapeutic Use.
MLN9708 (Cat No.:I000957), also known as ixazomib, is a proteasome inhibitor developed as an anticancer agent. It belongs to the class of boron-containing compounds and is a second-generation proteasome inhibitor derived from bortezomib. MLN9708 selectively and reversibly inhibits the chymotrypsin-like activity of the 20S proteasome, which plays a crucial role in protein degradation and cellular homeostasis. By inhibiting the proteasome, MLN9708 disrupts protein turnover, accumulating misfolded or unwanted proteins and subsequent induction of apoptosis in cancer cells. It has shown efficacy in various hematologic malignancies and solid tumors and has been approved for treating multiple myeloma.
Catalog Number | I000957 |
CAS Number | 1239908-20-3 |
Molecular Formula | C20H23BCl2N2O9 |
Purity | ≥95% |
Target | 20S Proteasome |
Solubility | DMSO 103 mg/mL; Water <1 mg/mL |
Storage | -20°C |
IC50 | 3.4 nM (MLN2238) |
IUPAC Name | (R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid |
InChI | InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1 |
InChIKey | MBOMYENWWXQSNW-AWEZNQCLSA-N |
SMILES | O=C(O)CC1(OB(OC1=O)C(NC(=O)CNC(=O)C2=CC(Cl)=CC=C2Cl)CC(C)C)CC(=O)O |
Reference | <p> |